Effect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study
Open Access
- 1 June 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 25 (6), 644-650
- https://doi.org/10.1038/ajh.2012.12
Abstract
Premature arterial stiffening and atherosclerosis are increased in patients with inflammatory arthropathies such as rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA). The proinflammatory protein calprotectin is associated with inflammatory arthropathies, vascular pathology, and acute coronary events. We examined the long-term effects of treatment with tumor necrosis factor (TNF)-α antagonists on aortic stiffness and carotid intima media thickness (CIMT) in patients with inflammatory arthropathies, and the relationships to the levels of calprotectin. Fifty-five patients with RA, AS, or PsA and a clinical indication for anti-TNF-α therapy were included and followed with regular examinations for 1 year. Thirty-six patients starting with anti-TNF-α therapy were compared with a nontreatment group of 19 patients. Examinations included assessments of aortic stiffness (aortic pulse wave velocity, aPWV), CIMT, and plasma calprotectin. After 1 year, aPWV (mean (s.d.)) was improved in the treatment group, but not in the control group (−0.54 [0.79] m/s vs. 0.06 [0.61] m/s, respectively; P = 0.004), and CIMT progression (median (quartile cut-points, 25th and 75th percentiles)) was reduced in the treatment group compared to the control group (−0.002 [–0.038, 0.030] mm vs. 0.030 [0.011, 0.043] mm, respectively; P = 0.01). In multivariable analyses, anti-TNF-α therapy over time was associated with improved aPWV (P = 0.02) and reduced CIMT progression (P = 0.04), and calprotectin was longitudinally associated with aPWV (P = 0.02). Long-term anti-TNF-α therapy improved aortic stiffness and CIMT progression in patients with inflammatory arthropathies. Calprotectin may be a soluble biomarker reflecting aortic stiffening in these patients.Keywords
This publication has 31 references indexed in Scilit:
- EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritisAnnals Of The Rheumatic Diseases, 2009
- Sustained improvement of vascular endothelial function during anti‐TNFα treatment in rheumatoid arthritis patientsScandinavian Journal of Rheumatology, 2009
- S100A8 and S100A9 Mediate Endotoxin-Induced Cardiomyocyte Dysfunction via the Receptor for Advanced Glycation End ProductsCirculation Research, 2008
- Expert consensus document on arterial stiffness: methodological issues and clinical applicationsEuropean Heart Journal, 2006
- Carotid intima-media thickness as a surrogate marker for cardiovascular disease in intervention studiesCurrent Medical Research and Opinion, 2006
- Carotid Intima-Media Thickness and Antihypertensive TreatmentStroke, 2006
- Differential expression and response to anti‐TNFα treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritisThe Journal of Pathology, 2005
- Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterolAtherosclerosis, 2004
- An integrated system for the non-invasive assessment of vessel wall and hemodynamic properties of large arteries by means of ultrasoundEuropean Journal of Ultrasound, 1999
- Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectinThe Lancet, 1990